한빛사
>
한빛사논문
한빛사논문
- 조회281
Children's Hospital of Philadelphia, 현 The Wistar Institute
Sci. Adv., Jun 12 2026, 12 (24) | https://doi.org/10.1126/sciadv.adv2687
Ready-to-load MHC-I nanoparticles for high-throughput T cell screening studies
Hoang Anh T. Phan1,2,3†, Soomin Eom1,3†, Daniel Hwang1,3, Michael C. Young1, Shirley M. Sun1,3,4, Molly C. Erdman1,3, Yi Sun1,2,3, Leena Mallik1,3, Photis Rotsides1,3, Mark M. Painter5,6, E. John Wherry5,6, Dimitri S. Monos2,7, Nikolaos G. Sgourakis1,2,3*
1Center for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
2Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
3Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
4Cancer Biology Graduate Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
5Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
6Institute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
7Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
*Corresponding author.
†These authors contributed equally to this work.
1Center for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
2Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
3Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
4Cancer Biology Graduate Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
5Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
6Institute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
7Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
*Corresponding author.
†These authors contributed equally to this work.
Abstract
MHC-I proteins present epitopic peptides to CD8+ T cells to elicit multifaceted adaptive immune responses. The affinity and avidity of interactions between peptide-MHC molecules and their cognate T cell receptors (TCRs) are fundamental parameters that contribute to the induction of activated or anergic T cell states. Here, we present a multivalent, loadable platform, VLP-Open HLA, featuring a virus-like particle (VLP) which can display up to 60 peptide/HLA [human leukocyte antigen (HLA)] molecules. VLP-Open HLA can be used to stain antigen-specific CD8+ T cells, providing a screening tool for orphan TCRs. When combined with costimulation, VLP-Open HLA acts as an artificial antigen-presenting platform to induce antigen-specific T cell activation and expansion, providing a facile alternative to autologous antigen-presenting cells. Our platform can be adapted to encompass multiple HLA allotypes and costimulatory molecules as mosaic nanoparticles, enabling a range of applications in experimental immunology.
논문정보
- Research article
- 2026년 06월 (BRIC 등록일 2026-06-15)
- 국외 연구진
- 생명과학 > 생물공학
댓글 작성 로그인
팝업 닫기
